Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
denenicokin + ipilimumab
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
**BMS-982470 + ipilimumab** is a combination therapy consisting of denenicokin (BMS-982470, also known as recombinant interleukin-21 or rIL-21) and ipilimumab. Denenicokin is an engineered form of interleukin-21, a cytokine that enhances immune system activity, particularly by activating natural killer (NK) cells and cytotoxic T-cells. Ipilimumab is a fully human monoclonal antibody that targets cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), acting as a checkpoint inhibitor to potentiate an anti-tumor immune response. This combination has been primarily investigated for the treatment of advanced or unresectable melanoma, aiming to synergistically enhance antitumor immune activity. The combination was studied in Phase I clinical trials in patients with stage III/IV unresectable melanoma[1][3][5][7].
- Other names
- recombinant interleukin-21 + ipilimumabIL-21 + ipilimumab
02
Targets
IL21R (Interleukin-21 receptor)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)
Beyond the preview
Go deeper on denenicokin + ipilimumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on denenicokin + ipilimumab.